{
    "clinical_study": {
        "@rank": "156249", 
        "arm_group": [
            {
                "arm_group_label": "Loteprednol etabonate", 
                "arm_group_type": "Active Comparator", 
                "description": "Topical Loteprednol etabonate eye drop 0.5%, 4 times a day, 3 weeks"
            }, 
            {
                "arm_group_label": "Dexamethasone", 
                "arm_group_type": "Active Comparator", 
                "description": "Topical Dexamethasone eye drop 0.1%, 4 times a day, 3 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Corticosteroid has been used for the treatment after phototherapeutic keratectomy (PRK).\n      Dexamethasone, a potent steroid can retard the corneal epithelial healing rate and has\n      numerous serious complications, especially glaucoma. Loteprednol, a new generation of\n      corticosteroid has less potency than dexamethasone and was proposed to has less side effect\n      regarding intraocular pressure (IOP) elevation.  Therefore, Investigators would like to\n      compare the effect of dexamethasone and loteprednol on corneal epithelial healing rate after\n      PRK and risk of glaucoma."
        }, 
        "brief_title": "Comparison the Effects of Dexamethasone and Loteprednol on Epithelial Healing", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Epithelial Defect After Phototherapeutic Keratectomy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  the patient with epithelial defect after phototherapeutic keratectomy\n\n        Exclusion Criteria:\n\n          -  the patient with systemic disease such as diabetes and connective tissue disease\n\n          -  the patient with ocular surface disease such as dry eye and recurrent corneal erosion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01724892", 
            "org_study_id": "othana001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Loteprednol etabonate", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dexamethasone", 
                "intervention_name": "Loteprednol etabonate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101", 
                "Loteprednol etabonate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 14, 2014", 
        "link": {
            "url": "http://www.ncbi.nlm.nih.gov/pubmed?term=dexamethasone%20AND%20loteprednol"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Khon Kaen", 
                        "country": "Thailand", 
                        "zip": "40002"
                    }, 
                    "name": "Onsiri Thanathanee"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Khon Kaen", 
                        "country": "Thailand", 
                        "zip": "40002"
                    }, 
                    "name": "Srinagarind Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "2", 
        "overall_official": {
            "affiliation": "Khon Kaen University", 
            "last_name": "Onsiri Thanathanee, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Thailand: Khon Kaen University Ethics Committee for Human Research", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "corneal epithelial healing", 
            "safety_issue": "Yes", 
            "time_frame": "1 month"
        }, 
        "reference": {
            "PMID": "22707339", 
            "citation": "Amon M, Busin M. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use. Int Ophthalmol. 2012 Oct;32(5):507-17. Epub 2012 Jun 16. Review."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01724892"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Khon Kaen University", 
            "investigator_full_name": "Onsiri Thanathanee", 
            "investigator_title": "othana", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "intraocular pressure", 
            "safety_issue": "Yes", 
            "time_frame": "6 month"
        }, 
        "source": "Khon Kaen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Khon Kaen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}